Skip to main content

Advertisement

Log in

Renal medullary carcinoma: a nearly fatal malignancy specifically affecting patients with a so-called benign condition

  • Case Report
  • Published:
CEN Case Reports Aims and scope Submit manuscript

Abstract

Renal medullary carcinoma (RMC) is a highly aggressive and rare malignancy found almost exclusively in young patients with sickle cell trait (SCT). Metastatic disease is commonly present at diagnosis. There is very limited experience treating disseminated disease and the prognosis is dismal. We report the case of a young 9-year-old boy with SCT, who presented with 4 months’ progression of abdominal pain, nausea and vomiting associated with cough spells, dysphagia, and weight loss. Upon evaluation, he was underweight, pale, and in mild respiratory distress. Cervical lymphadenopathy was evident and abdomen was diffusely tender. A whole-body CT scan showed a left kidney lesion with associated cervical, mediastinal, and retroperitoneal lymphadenopathy. Biopsy of a cervical lymph node revealed metastatic RMC. Patient was started on combination chemotherapy with paclitaxel, carboplatin, and gemcitabine followed by left adrenalectomy. In spite of having advanced disease, our patient achieved an excellent response with a progression-free survival of 17 months. Although SCT is thought to be a “benign” condition, RMC is one devastating complication associated with it. Considering its rarity, the near uniform associated fatality should prompt the question of whether clinical practice should change regarding proper counseling of these patients and raise awareness in the medical community.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bucknor MD, Goo JS, Coppolino ML. The risk of potential thromboembolic, renal and cardiac complications of sickle cell trait. Hemoglobin. 2014;38(1):28–32.

    Article  CAS  PubMed  Google Scholar 

  2. Davis CJ, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma: the seventh sickle cell nephropathy. Am J Surg Pathol. 1995;19(1):1–11.

    Article  PubMed  Google Scholar 

  3. Alvarez O, Rodriguez MM, Jordan L, Sarnaik S. Renal medullary carcinoma and sickle cell trait: a systematic review. Pediatr Blood Cancer. 2015;62(10):1694–9.

    Article  PubMed  Google Scholar 

  4. Hakimi AA, Koi PT, Milhoua PM, Blitman NM, Li M, Hugec V, et al. Renal medullary carcinoma: the Bronx experience. Urology. 2007;70(5):878–82.

    Article  PubMed  Google Scholar 

  5. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066.

    Article  PubMed  Google Scholar 

  6. Rathmell WK, Monk JP. High-dose-intensity MVAC for advanced renal medullary carcinoma: report of three cases and literature review. Urology. 2008;72:659–63.

    Article  PubMed  Google Scholar 

  7. Strouse JJ, Spevak M, Mack AK, Arceci RJ, Small D, Loeb DM. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer. 2005;44:407–11.

    Article  PubMed  Google Scholar 

  8. Diao B, Paule B, Esquivel S, Abbou CC, Salomon L, De La Taille A. Renal medullary carcinoma: remission with gemcitabine–cisplatin and review of therapeutic perspectives. Prog Urol. 2010;20:538–41.

    Article  CAS  PubMed  Google Scholar 

  9. Walsh A, Kelly DR, Vaid YV, Hilliard LM, Friedman GK. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr Blood Cancer. 2010;55:1217–20.

    Article  PubMed  Google Scholar 

  10. Strouse JJ, Spevak M, Mack AK, et al. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer. 2005;44:407–11.

    Article  PubMed  Google Scholar 

  11. Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol. 2006;24:e14.

    Article  PubMed  Google Scholar 

  12. Schaeffer EM, Guzzo TJ, Furge KA, et al. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int. 2010;106:62–5.

    Article  PubMed  Google Scholar 

  13. Johnson ED, Tannir NN, Olejeme KA, et al. Survival benefit in bevacizumab-based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma. J Clin Oncol. 2009;27(15S):e16096.

    Google Scholar 

  14. Liu Q, Galli S, Srinivasan R, Linehan WM, Tsokos M, Merino MJ. Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation. Am J Surg Pathol. 2013;37(3):368–74.

    Article  PubMed  Google Scholar 

  15. Swartz MA, Karth J, Schneider DT, et al. Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology. 2002;60:1083–9.

    Article  PubMed  Google Scholar 

  16. Calderaro J, Moroch J, Pierron G, et al. SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology. 2012;61(3):428–35.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We declare no funding source for our work.

Author information

Authors and Affiliations

Authors

Contributions

YGV did the literature review, obtained the radiologic images, and wrote the article. GC and NB contributed to the literature review and to the correction of the first draft. MC provided the pathology images and helped to correct the first draft. All authors were directly involved in the care of the patient.

Corresponding author

Correspondence to Yamila Goenaga-Vázquez.

Ethics declarations

Conflict of interest

All the authors have declared no competing interest.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goenaga-Vázquez, Y., Colón, G., Barrios, N. et al. Renal medullary carcinoma: a nearly fatal malignancy specifically affecting patients with a so-called benign condition. CEN Case Rep 7, 121–126 (2018). https://doi.org/10.1007/s13730-018-0308-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13730-018-0308-3

Keywords

Navigation